ライフサイエンスコーパス: contrast media

1 ion after applying 75 ml iodinated non-ionic contrast media).

2 onal methodological steps such as the use of contrast media.

3 ac MR imaging with an emphasis on the use of contrast media.

4 n permeability values generated with the two contrast media.

5 between thrombus-related events and type of contrast media.

6 lopment of new classes of magnetic resonance contrast media.

7 c LOCM alone, and eight with combinations of contrast media.

8 d with intravenously and orally administered contrast media.

9 ion) ranked similarly for ionic and nonionic contrast media.

10 tal ADEs are uncommon relative to the use of contrast media.

11 associated with LOCM than with conventional contrast media.

12 eased incidence of adverse events related to contrast media.

13 ease was associated with the use of nonionic contrast media.

14 submitted were reviewed for use of iodinated contrast media.

15 ere measured during power injection of three contrast media.

16 risk of thrombosis with the use of nonionic contrast media.

17 zed to receive nonionic or ionic low osmolar contrast media.

18 mated power injectors are used to administer contrast media.

19 ion after applying 70 ml iodinated non-ionic contrast media.

20 alow-field NMR polarimetry of hyperpolarized contrast media.

21 laxis to substances such as gadolinium-based contrast media.

22 ease patients who are often not suitable for contrast media.

23 48 hours before and after CT with or without contrast media.

24 most frequent adverse reaction to iodinated contrast media.

25 31 103) or without (n = 37 584) exposure to contrast media.

26 of the current global shortage of iodinated contrast media.

27 procedures and DPT with skin tests negative contrast media.

28 r iodixanol 270 or low-osmolar iopromide 300 contrast media.

29 unction (n = 307) who received intravascular contrast media.

30 e aware of the risk factors for reactions to contrast media.

31 ssue characteristics in the presence of high contrast media.

32 Its weakness is its low sensitivity towards contrast media.

33 w studies were done in patients receiving IV contrast media.

34 orter activity without exposing the fetus to contrast media.

35 te dimeglumine in patients who received both contrast media.

36 nce (MR) imaging with two different doses of contrast media.

37 ivity of ionic and non-ionic preparations of contrast media.

38 nistration of iodinated and tungsten cluster contrast media.

39 of the load was due to persistent iodinated contrast media.

40 e a simple strategy to define a safe dose of contrast media.

41 mately 3.6 times higher with all low-osmolar contrast media (2.3%) than with high-osmolar media (0.6%

42 of AN were diagnostic agents including X-ray contrast media (20.3%) and biological agents including h

43 9%), iodinated or magnetic resonance imaging contrast media (4.2%), immunotherapy and vaccines (3.9%)

44 he requirement of administration of multiple contrast media ((99m)Tc-SC and isosulfan blue), unwieldy

45 Contrast media administered during cardiac catheterizati

46 anesthesia with and without gadolinium-based contrast media administration (Dotarem; Guerbet).

47 anesthesia with and without gadolinium-based contrast media administration (Dotarem; Guerbet).

48 Purpose To investigate whether intravenous contrast media administration during CT is associated wi

49 (REnal Insufficiency Following Contrast MEDIA Administration TriaL IV [REMEDIALIV]: NCT

50 trast-induced AKI (CI-AKI; ie, AKI caused by contrast media administration) from contrast-associated

51 ssociated AKI (CA-AKI; ie, AKI coincident to contrast media administration).

52 ons is to decrease the dose and frequency of contrast media administration, especially in patients wi

53 hyperenhanced and hypoenhanced regions after contrast media administration.

54 portunity for customization of positive oral contrast media administration.

55 and abdomen in the portal venous phase after contrast media administration.

56 One hundred ninety-eight gadolinium-based contrast media administrations (99 with gadoxetate disod

57 d antiplatelet effects of ionic and nonionic contrast media after angiographic or clinical outcomes i

58 t reduction in CIN risk with the iso-osmolar contrast media agent iodixanol compared with a diverse g

59 Manganese-based contrast media allowed precise labeling of viable cardio

60 were associated with use of high-osmolality contrast media alone, 32 with ionic LOCM alone, 214 with

61 ce) by using extracellular and blood pool MR contrast media and after death.

62 ly ill patients commonly depend on iodinated contrast media and consequently pose the risk of contras

63 y/vascular interventions depend on iodinated contrast media and consequently pose the risk of contras

64 x CT examination, with use of oral and colon contrast media and contiguous, thin-collimation, helical

65 College of Radiology Committee on Drugs and Contrast Media and expert allergists/immunologists inclu

66 common complication of procedures requiring contrast media and is associated with increased short- a

67 of protein rich lymphatic fluid rather than contrast media and is used in the present study to visua

68 sing hyperpolarized proton and carbon-13 MRI contrast media and low-field (47.5 mT) preclinical scale

69 malpractice lawsuits associated with use of contrast media and outcomes from these lawsuits.

70 ate the cardiovascular effect of iso-osmolar contrast media and the image quality achieved.

71 Overall adverse events related to contrast media and those for which treatment was necessa

72 ibiotics, cardiovascular drugs, painkillers, contrast media, and antiepileptic drugs have been record

73 ssessed by a technician blinded to the study contrast media, and clinical events were monitored by an

74 in radiology, more available techniques and contrast media, and expanded knowledge around their indi

75 rdiac MRI with and without administration of contrast media, and non-cardiac-gated multidetector CT (

76 rdiac MRI with and without administration of contrast media, and non-cardiac-gated multidetector CT w

77 s, antimycotics, antivirals, iodinated X-ray contrast media, antiinflamatory, cytostatics, diuretics,

78 ecially in patients with contraindication to contrast media application.

79 ionic and non-ionic preparations of the MRI contrast media are able to induce mast cell degranulatio

80 Excess volumes of contrast media are associated with renal complications i

81 Intravenous iodinated contrast media are commonly used with CT to evaluate dis

82 Iodine contrast media are essential components of many imaging

83 Because contrast media are excreted by the kidney, we hypothesiz

84 Life-threatening reactions to radiographic contrast media are rare.

85 In particular, these contrast media are well tolerated in patients with renal

86 Nontherapeutical agents, such as contrast media, are also involved.

87 e mast cells markedly more weakly than ionic contrast media at identical concentration.

88 ptimal timing of the CT scan relative to the contrast media bolus remains a challenging task given th

89 Radiological contrast media, both iodinated and gadolinium-based, can

90 fusion sequences in that it does not require contrast media, but rather uses the signals emitted by p

91 t county health system to conserve iodinated contrast media by optimizing contrast media use in the C

92 rees ) during 1 hour after administration of contrast media by using a 1.5-T MR unit.

93 Both contrast media caused similarly small but statistically

94 ute phase begins upon exposure to gadolinium contrast media, characterized by a systemic inflammatory

95 oroquinolones, chlorhexidine, opioids, radio contrast media, chemotherapeutics, biological agents, no

96 iate hypersensitivity reactions to iodinated contrast media (CM) are common.

97 ere assessed at 2, 6, 24, and 48 hours after contrast media (CM) exposure in 458 high-risk patients (

98 CT showed subintimal staining from undiluted contrast media (CM) in the aortic root with no communica

99 spectively develop individualized low-volume contrast media (CM) protocols adapted to tube voltage in

100 Contrast media (CM) volume minimization has been advocat

101 Contrast media (CM) were first used soon after the disco

102 vastatin group (80 mg within 24 hours before contrast media [CM] exposure; n=202) or (2) the control

103 With high-osmolar contrast media compared with the three noncharged low-os

104 suffering from chronic kidney disease (CKD), contrast media compatible with renal impairment is sorel

105 o correlate with the area under the curve of contrast media concentration over time.

106 l shortage and rapid deployment of iodinated contrast media conservation strategies.

107 Pioneers and pathfinders in the field of contrast media development and radiologic procedures hel

108 nd adolescents was very low, and exposure to contrast media did not increase the risk consistently fo

109 n signal attenuation at equilibrium state of contrast media distribution (10 minutes) was significant

110 ive information about tissue composition and contrast media distribution.

111 To detect extravasation of contrast media during mechanical power injection at dyna

112 of antibiotic and antimycotic agents to ERC contrast media efficiently reduced post-ERC infectious e

113 Iodinated contrast media enable greater attenuation of vascular an

114 Purpose To develop a dual-energy contrast media-enhanced computed tomographic (CT) protoc

115 ce increasing due to an increasing number of contrast media-enhanced radiological procedures being pe

116 puted tomography (CT), before and after i.v. contrast media enhancement.

117 xamination involving increased radiation and contrast media exposure and institutional expenses.

118 The associations between contrast media exposure and outcome were estimated by us

119 After propensity score weighting, contrast media exposure was associated with higher risk

120 with eGFR greater than 45 mL/min/1.73.m(2), contrast media exposure was not associated with higher A

121 Inappropriate management of contrast media extravasation (27% [41 of 151]) and alleg

122 s of intravenously administered radiographic contrast media fail to demonstrate renal damage.

123 patients who received intravenous iodinated contrast media for CT.

124 olarized (129)Xe and (3)He are gases used as contrast media for magnetic resonance imaging that provi

125 ide (Ta2O5) nanoparticles (NPs) as new X-ray contrast media for microcomputed tomography (muCT) imagi

126 Injection of contrast media for rapid measurement of contrast fractio

127 have renal insufficiency and are exposed to contrast media formulated with gadolinium.

128 %) of 105 607 injections of gadolinium-based contrast media (gadopentetate dimeglumine, 31 540; gadob

129 tory of group I intravenous gadolinium-based contrast media (GBCM) administration presented with clin

130 II or group III intravenous gadolinium-based contrast media (GBCM).

131 between the iodixanol 270 and iopromide 300 contrast media groups (469 HU +/- 167 vs 447 HU +/- 166,

132 following exposure to intravenous iodinated contrast media has been overstated.

133 The osmotic characteristics of contrast media have been a significant focus in many inv

134 Echocardiographic contrast media have been used to assess myocardial perfu

135 Technological progress and novel contrast media have resulted in optoacoustic imaging bei

136 nistration of either LOCM or high-osmolality contrast media (HOCM) were reviewed.

137 land enlargement following iodine-containing contrast media (ICCM), also known as iodide mumps (IM),

138 cumented side effect of the use of iodinated contrast media (ICM) administered intravenously.

139 screening for the detection of six iodinated contrast media (ICM) and their phototransformation produ

140 Iodinated contrast media (ICM) are commonly administered pharmaceu

141 iological procedures utilising intravascular contrast media (ICM) are fundamental to modern medicine,

142 ogical wastewater treatment, iodinated X-ray contrast media (ICM) have been detected in municipal was

143 The transformation of the iodinated X-ray contrast media (ICM) iopamidol, iopromide, iohexol, iome

144 Intravenous iodinated contrast media (ICM) is widely used in the United States

145 as impacted global availability of iodinated contrast media (ICM).

146 g the post-treatments consisted of iodinated contrast media (ICM).

147 stem is able to discriminate gold and iodine contrast media in different organs in vivo.

148 Separation of two vascular contrast media in different vascular phases enabled acqu

149 lantation, prevention by avoiding gadolinium contrast media in patients with chronic kidney disease i

150 application of antimicrobial agents into ERC contrast media in preventing post-ERC infectious complic

151 ring complication associated with the use of contrast media in radiological studies.

152 PA) and necrosis-specific (mesoporphyrin) MR contrast media in rats.

153 dinated and gadolinium (Gd)-based CT and MRI contrast media in renally compromised patients.

154 o 90 patients who were administered the same contrast media in reverse order (180 patients).

155 n appropriate volumes are useful alternative contrast media in selected high-risk patients undergoing

156 rostheses that had inlays of water, fat, and contrast media in the pelvis was used to optimize the IF

157 l maps, radiologists can optimise the use of contrast media in these CTs, thus allowing lower doses o

158 hancement of selected pairs of complementary contrast media in vivo.

159 The use of gadolinium contrast-media in MRI studies increases both the reliabi

160 The most important adverse effects of contrast media include hypersensitivity reactions, thyro

161 enabling new ways of sensing hyperpolarized contrast media, including most notably [1-(13)C]pyruvate

162 R of 0.96 (95% CI: 0.94, 0.99; P = .01), and contrast media increased risk in the subgroup analysis,

163 Iodinated radiographic contrast media induce transient, submaximal hyperemia.

164 junction is achieved with a quadruple-phase contrast media injection protocol.

165 ith a single 7.5-minute scan and single-dose contrast media injection, mpDYCI can simultaneously quan

166 available high-osmolar and four low-osmolar contrast media (ioxaglate, iohexol, iopamidol, and iover

167 kidney disease, in whom the use of iodinated contrast media is a limitation.

168 e overall safety profile of gadolinium-based contrast media is excellent.

169 s for pediatric anaphylaxis from intravenous contrast media is insufficient.

170 romising new developments include blood pool contrast media, labeling of myocardial precursor cells,

171 ast medium (IOCM) iodixanol with low-osmolar contrast media (LOCM) and to identify predictors of cont

172 Toxicity resulting from retained contrast media may cause adverse cardiovascular outcomes

173 teria, suggesting that intravenous iodinated contrast media may not be the causative agent in diminis

174 Novel contrast media may potentially be used to detect pathoph

175 ry (AKI) after intravenous administration of contrast media might be overstated, the risk in patients

176 r disposing of waste and residues (including contrast media); minimizing the environmental impact of

177 Evaluation of the enhancement after contrast media (n=29) showed mean enhancement +/-SD of 2

178 ne the influence of the gadolinium-based MRI contrast media on histamine release from mast cells and

179 The influence of the classical, iodine-based contrast media on mastocyte degranulation has been fully

180 Purpose To assess the effect of intravenous contrast media on renal function in neonates.

181 n allergies, and prior exposure to iodinated contrast media on two occasions (2 months and 5 years be

182 the phrases "contrast," "contrast medium," "contrast media," or "radiocontrast" and any of the words

183 At meta-regression, studies in which contrast media (P = .03) and diffusion-weighted imaging

184 Clear separation of each of the contrast media pairs was seen in the phantom and in both

185 ostprocedural heparin, and a lower amount of contrast media per case (P<0.05).

186 rs and postprocedural heparin, and amount of contrast media per case.

187 Radiological contrast media play an essential role in radiology depar

188 l medical status, previous administration of contrast media, procedural information, occurrence and c

189 Iodinated contrast media produce non-immediate hypersensitivity re

190 wide range of applications in hyperpolarized contrast media production-and beyond.

191 College of Radiology Committee on Drugs and Contrast Media propose a new term for symptoms reported

192 CNR, which was translated into a low-volume contrast media protocol demonstrating noninferior image

193 All CT and contrast media protocol parameters were kept identical a

194 In the first group of participants, the same contrast media protocol was used for both scans.

195 noninferior image quality of the low-volume contrast media protocol with PCD CT.

196 Blood-pool contrast media provide persistent signal enhancement in

197 Albumin-binding gadolinium-based contrast media provided a longer imaging window, but inf

198 Cephalosporins, clindamycin, and radio contrast media (RCM) were mainly involved in subsequent

199 and low-field-strength applications, iodine contrast media recycling programs in cardiac CT, judicio

200 ry angioplasty, the use of ionic low osmolar contrast media reduces the risk of ischemic complication

201 after angioplasty, patients receiving ionic contrast media reported significantly fewer symptoms of

202 e especially intraarterial administration of contrast media represents a cause of hospital-acquired a

203 n after incubation with the solutions of MRI contrast media results from non-specific osmotic stimula

204 IV saline in patients receiving low-osmolar contrast media (RR, 0.65 [CI, 0.33 to 1.25]; low SOE), s

205 in which nursing practice can contribute to contrast media safety management in a diagnostic imaging

206 Iodide-containing medications and contrast media should be avoided in patients with functi

207 Therefore, low osmolar ionic contrast media should be strongly considered when perfor

208 Furthermore, contrast media should be used with caution because of th

209 logies, safety issues related to new imaging contrast media, standardisation of image acquisition acr

210 It was also proved that the non-ionic MRI contrast media stimulate mast cells markedly more weakly

211 rosmotic, orally administered, water-soluble contrast media such as Gastrografin are theoretically ca

212 e used to monitor the first-pass dynamics of contrast media, thus defining selective regional myocard

213 nt-specific individualized trigger delay for contrast media timing with bolus tracking.

214 hyperthyroidism after injection of iodinated contrast media to evaluate a left hemipelvis mass.

215 diac-gated multidetector CT with and without contrast media to rule out pulmonary embolism.

216 ted multidetector CT (MDCT) with and without contrast media to rule out pulmonary embolism.

217 The ratio of the volume of contrast media to the creatinine clearance (V/CrCl) has

218 lts without contraindication to iodine-based contrast media underwent same-day cardiac PCD CT and MRI

219 serve iodinated contrast media by optimizing contrast media use in the CT department and changing ord

220 The contrast media varied in viscosity from a thin barium li

221 However, contrast media volume and osmolality may affect the degr

222 e same or lower CT dose index and equivalent contrast media volume as EID-CT.

223 valent or lower CT dose index and equivalent contrast media volume as the clinical scan.

224 Contrast media volume in the second group (n = 60) was r

225 ared with EID CT served as the reference for contrast media volume reduction in the second group.

226 nts, selective/nonselective catheterization, contrast media volume, and time of procedure were determ

227 al for photon-counting detector CT to reduce contrast media volumes, utility of combined PET/MRI in t

228 Intrathecal injection of nonionic contrast media was associated with 235 reported serious,

229 R less than 30 mL/min/1.73 m(2), exposure to contrast media was associated with a higher AKI risk (48

230 The use of antimicrobials in contrast media was associated with a significant decreas

231 ncomycin, gentamicin and fluconazol into ERC contrast media was evaluated in a case-control design.

232 Contrast media were administered orally and by means of

233 d intravenous and bismuth subsalicylate oral contrast media were administered.

234 c-like reactions related to gadolinium-based contrast media were assessed 2 years before and 3.5 year

235 nonfatal ADEs; intrathecal ionic [corrected] contrast media were associated with 14 such reported ADE

236 High-osmolality contrast media were associated with 512 serious, nonfata

237 ta from 1980 to 1984, when only high-osmolar contrast media were available.

238 IV and oral contrast media were then digitally subtracted using dual

239 nd of radiological signs that do not require contrast-media were analyzed.

240 on can be achieved with iso- and low-osmolar contrast media when it is injected at the same iodine de

241 rpolarized (129)Xe gas and [1-(13)C]pyruvate contrast media (which was compared to the (13)C polarime

242 ower doses of radiation and lower volumes of contrast media while achieving the same CT values and ev

243 MHz) comparable with that of commercial MRI contrast media, while the oxidized form has negligible r

244 nistration, favouring the use of alternative contrast media with confirmed tolerance instead of the i

245 heters should tolerate power injection of CT contrast media with peak pressures remaining below the m

246 ic images that boost the signal of iodinated contrast media within the stent lumen or high monoenerge